Condition

Accelerated Intimal Hyperplasia (1)

Diabetic Kidney Disease (1)

Hepatocellular Carcinoma (1)

Non-small Cell Lung Cancer (1)

Pancreatic Ductal Adenocarcinoma (1)

Overall Status

Active, not recruiting (1)

Completed (1)

Recruiting (1)

Terminated (1)

Phase

phase 2 (2)

phase 1 (1)

phase 1/phase 2 (1)

Sponsor

Bristol-Myers Squibb (2)

Icahn School of Medicine at Mount Sinai (1)

Washington University School of Medicine (1)

Collaborator

Bristol-Myers Squibb (2)

National Cancer Institute (NCI) (1)

National Institutes of Health (NIH) (1)

The Foundation for Barnes-Jewish Hospital (1)

Study Documents

Intervention Type

drug (4)

procedure (1)

Funder Type

Industry (2)

Other (2)

Study Type

Interventional (4)

bms-813160

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Pancreatic Ductal Adenocarcinoma Trial in Saint Louis (BMS-813160, Nivolumab, Gemcitabine)

Active, not recruiting

Has Results

Pancreatic Ductal Adenocarcinoma

BMS-813160
+5 more

Saint Louis, Missouri

Washington University School of Medicine

Dec 8, 2022

NSCLC, Hepatocellular Carcinoma Trial in New York (Nivolumab, BMS-813160, BMS-986253)

Recruiting

Non-small Cell Lung Cancer
Hepatocellular Carcinoma

Nivolumab
+2 more

New York, New York

Icahn School of Medicine at Mount Sinai

Oct 14, 2021

Diabetic Kidney Disease Trial in Worldwide (BMS-813160, Placebo matching with BMS-813160)

Terminated

Has Results

Diabetic Kidney Disease

BMS-813160
Placebo matching with BMS-813160

Birmingham, Alabama
+61 more

Jul 26, 2019

Accelerated Intimal Hyperplasia Trial in Madison (BMS-813160, [14C] BMS-813160, Placebo)

Completed

Accelerated Intimal Hyperplasia

BMS-813160
+2 more

Madison, Wisconsin

Covance Clinical Research Unit, Inc.

Feb 10, 2011